SE9502244D0 - A composition and a process for the preparation thereof - Google Patents
A composition and a process for the preparation thereofInfo
- Publication number
- SE9502244D0 SE9502244D0 SE9502244A SE9502244A SE9502244D0 SE 9502244 D0 SE9502244 D0 SE 9502244D0 SE 9502244 A SE9502244 A SE 9502244A SE 9502244 A SE9502244 A SE 9502244A SE 9502244 D0 SE9502244 D0 SE 9502244D0
- Authority
- SE
- Sweden
- Prior art keywords
- composition
- pct
- glass
- active agent
- plasticizer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Glass Compositions (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Processing Of Solid Wastes (AREA)
- Medicines Containing Plant Substances (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9502244A SE9502244D0 (sv) | 1995-06-20 | 1995-06-20 | A composition and a process for the preparation thereof |
AU62473/96A AU695622B2 (en) | 1995-06-20 | 1996-06-19 | A composition comprising an active agent dissolved in a glass-forming carrier and a process for the preparation thereof |
PT96921197T PT833611E (pt) | 1995-06-20 | 1996-06-19 | Composicao que compreendendo um agente activo dissolvido num veiculo formador de vidro e processo para a sua preparacao |
EP96921197A EP0833611B1 (en) | 1995-06-20 | 1996-06-19 | A composition comprising an active agent dissolved in a glass-forming carrier and a process for the preparation thereof |
AT96921197T ATE204466T1 (de) | 1995-06-20 | 1996-06-19 | Zusammensetzung, die ein in einem glasbildenden träger gelösten wirkstoff enthalt und ein verfahren zu deren herstellung |
CA002225286A CA2225286C (en) | 1995-06-20 | 1996-06-19 | A composition comprising an active agent dissolved in a glass-forming carrier and a process for the preparation thereof |
PCT/SE1996/000806 WO1997000670A1 (en) | 1995-06-20 | 1996-06-19 | A composition comprising an active agent dissolved in a glass-forming carrier and a process for the preparation thereof |
NZ311208A NZ311208A (en) | 1995-06-20 | 1996-06-19 | Composition comprising an active agent dissolved in a glass-forming carrier comprising a glass-forming substance containing a plasticizer, composition is liquid or jelly-like below 50 degrees |
DK96921197T DK0833611T3 (da) | 1995-06-20 | 1996-06-19 | Sammensætning omfattende et aktivt middel opløst i en glasdannende bærer og fremgangsmåde til fremstilling heraf |
DE69614689T DE69614689T2 (de) | 1995-06-20 | 1996-06-19 | Zusammensetzung, die ein in einem glasbildenden träger gelösten wirkstoff enthalt und ein verfahren zu deren herstellung |
US08/973,902 US6083518A (en) | 1995-06-20 | 1996-06-19 | Composition comprising an active agent dissolved in a glass-forming carrier and a process for the preparation thereof |
DE0833611T DE833611T1 (de) | 1995-06-20 | 1996-06-19 | Zusammensetzung, die ein in einem glasbildenden träger gelösten wirkstoff enthalt und ein verfahren zu deren herstellung |
ES96921197T ES2118677T3 (es) | 1995-06-20 | 1996-06-19 | Una composicion que comprende un agente activo disuelto en un vehiculo formador de vidrio y un procedimiento para su preparacion. |
JP50378997A JP4020331B2 (ja) | 1995-06-20 | 1996-06-19 | ガラス形成性担体に溶解した活性物質からなる組成物及びその製造方法 |
ZA965237A ZA965237B (en) | 1995-06-20 | 1996-06-20 | A composition and a process for the preparation thereof |
HK98109537A HK1008774A1 (en) | 1995-06-20 | 1998-07-29 | A composition comprising an active agent dissolved in a glass-forming carrier and a process for the preparation thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9502244A SE9502244D0 (sv) | 1995-06-20 | 1995-06-20 | A composition and a process for the preparation thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SE9502244D0 true SE9502244D0 (sv) | 1995-06-20 |
Family
ID=20398685
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE9502244A SE9502244D0 (sv) | 1995-06-20 | 1995-06-20 | A composition and a process for the preparation thereof |
Country Status (15)
Country | Link |
---|---|
US (1) | US6083518A (ja) |
EP (1) | EP0833611B1 (ja) |
JP (1) | JP4020331B2 (ja) |
AT (1) | ATE204466T1 (ja) |
AU (1) | AU695622B2 (ja) |
CA (1) | CA2225286C (ja) |
DE (2) | DE833611T1 (ja) |
DK (1) | DK0833611T3 (ja) |
ES (1) | ES2118677T3 (ja) |
HK (1) | HK1008774A1 (ja) |
NZ (1) | NZ311208A (ja) |
PT (1) | PT833611E (ja) |
SE (1) | SE9502244D0 (ja) |
WO (1) | WO1997000670A1 (ja) |
ZA (1) | ZA965237B (ja) |
Families Citing this family (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6136814A (en) * | 1997-12-08 | 2000-10-24 | Fujisawa Usa, Inc. | Aqueous acyclovir product |
SE9801704D0 (sv) * | 1998-05-14 | 1998-05-14 | Bioglan Ab | Biologically active composition |
SE9801705D0 (sv) * | 1998-05-14 | 1998-05-14 | Bioglan Ab | Biologically active composition |
AU3885901A (en) * | 1999-09-21 | 2001-04-24 | Emory University | Methods and compositions for treating platelet-related disorders |
EP1175205B1 (en) * | 1999-11-12 | 2006-06-14 | Abbott Laboratories | Solid dispersion comprising ritonavir, fenofibrate or griseofulvin |
US7364752B1 (en) | 1999-11-12 | 2008-04-29 | Abbott Laboratories | Solid dispersion pharamaceutical formulations |
DE10026698A1 (de) * | 2000-05-30 | 2001-12-06 | Basf Ag | Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung |
JP4512700B2 (ja) * | 2003-06-02 | 2010-07-28 | トーアエイヨー株式会社 | アシクロビル含有水溶液製剤 |
US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
US20050101605A1 (en) * | 2003-11-07 | 2005-05-12 | Ahmed Salah U. | Oral liquid formulations of methotrexate |
JP4896006B2 (ja) | 2004-04-08 | 2012-03-14 | バイオマトリカ, インコーポレイテッド | ライフサイエンスのためのサンプル保存とサンプル管理との統合 |
CN101583620B (zh) | 2005-11-28 | 2016-08-17 | 马里纳斯医药公司 | 加奈索酮组合物及其制备和使用方法 |
GB2432528B (en) * | 2005-11-29 | 2011-04-06 | Ian Ripley | Anti-viral compositions comprising flavanone glycosides and fruit acids |
CA2645070C (en) * | 2006-03-08 | 2014-02-04 | Nihon Nohyaku Co., Ltd. | Pharmaceutical composition for external use |
EP2025337B1 (en) * | 2006-03-08 | 2014-09-10 | Nihon Nohyaku Co., Ltd. | Pharmaceutical composition for external use |
RU2415669C2 (ru) | 2006-03-08 | 2011-04-10 | Нихон Нохияку Ко., Лтд. | Фармацевтическая композиция для наружного применения |
CA2653782A1 (en) | 2006-06-14 | 2007-12-21 | Dr. Reddy's Laboratories Limited | Topical compositions |
EP2526933B1 (en) | 2006-09-22 | 2015-02-25 | Pharmacyclics, Inc. | Inhibitors of Bruton's tyrosine kinase |
KR100721126B1 (ko) | 2006-12-28 | 2007-05-23 | (주)바이오앤에이치엔티 | 모기 기피제 조성물 |
KR20100075476A (ko) | 2007-09-05 | 2010-07-02 | 가부시키가이샤 폴라 파마 | 항진균 조성물 |
JP5453093B2 (ja) * | 2007-09-05 | 2014-03-26 | 株式会社ポーラファルマ | 抗真菌医薬組成物 |
CN101808637B (zh) | 2007-09-05 | 2013-07-24 | 宝丽制药股份有限公司 | 医药组合物 |
CA2699157A1 (en) | 2007-09-10 | 2009-03-19 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
CA2719358C (en) | 2008-03-31 | 2017-10-24 | Altan Co., Ltd. | Antiviral agent and antiviral composition |
GB2462022B (en) | 2008-06-16 | 2011-05-25 | Biovascular Inc | Controlled release compositions of agents that reduce circulating levels of platelets and methods thereof |
TWI392673B (zh) | 2008-08-27 | 2013-04-11 | Calcimedica Inc | 調控細胞內鈣離子濃度之化合物 |
EA021943B1 (ru) * | 2009-01-09 | 2015-10-30 | Эгиш Дьёдьсердьяр Ньильваношан Мюкеде Ресвеньтаршашаг | Способ изготовления вагинального суппозитория |
WO2010093992A1 (en) * | 2009-02-13 | 2010-08-19 | Topica Pharmaceuticals, Inc | Anti-fungal formulation |
EP2416757A2 (en) | 2009-04-09 | 2012-02-15 | Pola Pharma Inc. | Antimycotic pharmaceutical composition |
KR101409792B1 (ko) | 2009-04-09 | 2014-06-19 | 니혼노야쿠가부시키가이샤 | 항진균성 약제학적 조성물 |
KR101754697B1 (ko) | 2009-08-25 | 2017-07-06 | 가부시키가이샤 폴라 파마 | 항진균성 약제학적 조성물 |
US7741330B1 (en) | 2009-10-12 | 2010-06-22 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase |
ES2602475T3 (es) | 2010-04-15 | 2017-02-21 | Tracon Pharmaceuticals, Inc. | Potenciación de la actividad anticáncer por terapia de combinación con inhibidores de la vía BER |
HUE029570T2 (en) | 2010-04-27 | 2017-03-28 | Calcimedica Inc | Intracellular calcium modifying compounds |
EP2563759B1 (en) | 2010-04-27 | 2022-04-06 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
US9376709B2 (en) | 2010-07-26 | 2016-06-28 | Biomatrica, Inc. | Compositions for stabilizing DNA and RNA in blood and other biological samples during shipping and storage at ambient temperatures |
US9845489B2 (en) | 2010-07-26 | 2017-12-19 | Biomatrica, Inc. | Compositions for stabilizing DNA, RNA and proteins in saliva and other biological samples during shipping and storage at ambient temperatures |
MX337711B (es) | 2010-08-27 | 2016-03-15 | Calcimedica Inc | Compuestos que modulan el calcio intracelular. |
US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
US9512116B2 (en) | 2012-10-12 | 2016-12-06 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
US9725703B2 (en) | 2012-12-20 | 2017-08-08 | Biomatrica, Inc. | Formulations and methods for stabilizing PCR reagents |
WO2015054283A1 (en) | 2013-10-08 | 2015-04-16 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
KR20160093675A (ko) | 2013-12-05 | 2016-08-08 | 파마싸이클릭스 엘엘씨 | 브루톤 티로신 키나제의 억제제 |
JP2017510624A (ja) | 2014-02-10 | 2017-04-13 | パタラ ファーマ リミテッド ライアビリティ カンパニー | 肥満細胞安定剤による全身性障害の治療 |
EP3725311A1 (en) | 2014-02-10 | 2020-10-21 | Respivant Sciences GmbH | Methods for the treatment of lung diseases with mast cell stabilizers |
WO2015164213A1 (en) | 2014-04-23 | 2015-10-29 | The Research Foundation For The State University Of New York | A rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjuction therewith |
CN106572650B (zh) | 2014-06-10 | 2021-08-31 | 生物马特里卡公司 | 在环境温度下稳定凝血细胞 |
US9839644B2 (en) | 2014-09-09 | 2017-12-12 | ARKAY Therapeutics, LLC | Formulations and methods for treatment of metabolic syndrome |
US9359316B1 (en) | 2014-11-25 | 2016-06-07 | Concentric Analgesics, Inc. | Prodrugs of phenolic TRPV1 agonists |
US10227333B2 (en) | 2015-02-11 | 2019-03-12 | Curtana Pharmaceuticals, Inc. | Inhibition of OLIG2 activity |
KR102629269B1 (ko) | 2015-02-27 | 2024-01-24 | 커타나 파마슈티칼스, 인크. | Olig2 활성의 억제 |
US10238625B2 (en) | 2015-08-07 | 2019-03-26 | Respivant Sciences Gmbh | Methods for the treatment of mast cell related disorders with mast cell stabilizers |
WO2017027402A1 (en) | 2015-08-07 | 2017-02-16 | Patara Pharma, LLC | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders |
EP4242628A3 (en) | 2015-12-08 | 2023-11-08 | Biomatrica, INC. | Reduction of erythrocyte sedimentation rate |
WO2017147146A1 (en) | 2016-02-23 | 2017-08-31 | Concentric Analgesics, Inc. | Prodrugs of phenolic trpv1 agonists |
EP3454945B1 (en) | 2016-05-12 | 2022-01-19 | The Regents Of The University Of Michigan | Ash1l inhibitors and methods of treatment therewith |
WO2017205534A1 (en) | 2016-05-25 | 2017-11-30 | Concentric Analgesics, Inc. | Prodrugs of phenolic trpv1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia |
WO2017205766A1 (en) | 2016-05-27 | 2017-11-30 | Pharmacyclics Llc | Inhibitors of interleukin-1 receptor-associated kinase |
WO2017205769A1 (en) | 2016-05-27 | 2017-11-30 | Pharmacyclics Llc | Inhibitors of interleukin-1 receptor-associated kinase |
WO2017205762A1 (en) | 2016-05-27 | 2017-11-30 | Pharmacyclics Llc | Inhibitors of interleukin-1 receptor-associated kinase |
MX2019002259A (es) | 2016-08-26 | 2019-09-18 | Curtana Pharmaceuticals Inc | Inhibicion de la actividad de la olig2. |
CN110139646A (zh) | 2016-08-31 | 2019-08-16 | 瑞思皮万特科学有限责任公司 | 用于治疗由特发性肺纤维化引起的慢性咳嗽的色甘酸组合物 |
WO2018067341A1 (en) | 2016-10-07 | 2018-04-12 | Patara Pharma, LLC | Cromolyn compositions for treatment of pulmonary fibrosis |
US11382897B2 (en) | 2017-11-07 | 2022-07-12 | The Regents Of The University Of Michigan | Therapeutic combination for treatment of cerebellar ataxia |
WO2019094772A1 (en) | 2017-11-10 | 2019-05-16 | The Regents Of The University Of Michigan | Ash1l degraders and methods of treatment therewith |
AU2018378935A1 (en) | 2017-12-07 | 2020-06-25 | The Regents Of The University Of Michigan | NSD family inhibitors and methods of treatment therewith |
US11685722B2 (en) | 2018-02-28 | 2023-06-27 | Curtana Pharmaceuticals, Inc. | Inhibition of Olig2 activity |
WO2019236957A1 (en) | 2018-06-07 | 2019-12-12 | The Regents Of The University Of Michigan | Prc1 inhibitors and methods of treatment therewith |
CA3107433A1 (en) | 2018-07-27 | 2020-01-30 | Concentric Analgesics, Inc. | Pegylated prodrugs of phenolic trpv1 agonists |
US20200069742A1 (en) | 2018-08-29 | 2020-03-05 | Myos Rens Technology Inc. | Methods for alleviating, inhibiting or reversing muscle disuse atrophy in mammals |
WO2020044114A2 (en) | 2018-08-29 | 2020-03-05 | Ftf Pharma Private Limited | Methotrexate pharmaceutical composition |
US20200108102A1 (en) | 2018-10-03 | 2020-04-09 | Myos Rens Technology Inc. | Spray dried follistatin product |
NL2021864B1 (en) * | 2018-10-24 | 2020-05-13 | Seranovo B V | Deep Eutectic Solvent Platform for Oral Pharmaceutical Formulations |
KR20210090179A (ko) | 2018-10-24 | 2021-07-19 | 세라노보 비.브이. | 경구 약제학적 제형용 공융용매 플랫폼 |
WO2020096660A1 (en) | 2018-11-06 | 2020-05-14 | Myos Rens Technology, Inc. | Methods and compositions for improving skeletal muscle protein fractional synthetic rate |
SG11202106304RA (en) | 2018-12-31 | 2021-07-29 | Biomea Fusion Llc | Irreversible inhibitors of menin-mll interaction |
WO2020160113A1 (en) | 2019-02-01 | 2020-08-06 | Myos Rens Technology Inc. | Egg yolk powder for improving quality of life and increasing activity in aging and chronically ill mammals |
BR112021018254A2 (pt) | 2019-03-15 | 2022-03-15 | Unicycive Therapeutics Inc | Derivados de nicorandil |
JP2023533982A (ja) | 2020-07-10 | 2023-08-07 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | Gas41阻害剤及びその使用方法 |
WO2022133064A1 (en) | 2020-12-16 | 2022-06-23 | Biomea Fusion, Inc. | Fused pyrimidine compounds as inhibitors of menin-mll interaction |
US20230120115A1 (en) | 2021-08-11 | 2023-04-20 | Biomea Fusion, Inc. | Covalent inhibitors of menin-mll interaction for diabetes mellitus |
WO2023027966A1 (en) | 2021-08-24 | 2023-03-02 | Biomea Fusion, Inc. | Pyrazine compounds as irreversible inhibitors of flt3 |
WO2023039240A1 (en) | 2021-09-13 | 2023-03-16 | Biomea Fusion, Inc. | IRREVERSIBLE INHIBITORS OF KRas |
WO2023086341A1 (en) | 2021-11-09 | 2023-05-19 | Biomea Fusion, Inc. | Inhibitors of kras |
US11945785B2 (en) | 2021-12-30 | 2024-04-02 | Biomea Fusion, Inc. | Pyrazine compounds as inhibitors of FLT3 |
WO2023235618A1 (en) | 2022-06-03 | 2023-12-07 | Biomea Fusion, Inc. | Fused pyrimidine compounds as inhibitors of menin |
WO2024086613A2 (en) | 2022-10-19 | 2024-04-25 | Myos Corp. | Myogenic compounds |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US33221A (en) * | 1861-09-03 | Improvement in soap | ||
US4151273A (en) * | 1974-10-31 | 1979-04-24 | The Regents Of The University Of California | Increasing the absorption rate of insoluble drugs |
USRE33221E (en) | 1982-04-29 | 1990-05-22 | American Dental Association Health Foundation | Dental restorative cement pastes |
US5389677B1 (en) * | 1986-12-23 | 1997-07-15 | Tristrata Inc | Method of treating wrinkles using glycalic acid |
EP0319988A1 (en) * | 1987-12-09 | 1989-06-14 | Showa Denko Kabushiki Kaisha | External dermatological composition |
US5215757A (en) * | 1991-03-22 | 1993-06-01 | The Procter & Gamble Company | Encapsulated materials |
US5162117A (en) * | 1991-11-22 | 1992-11-10 | Schering Corporation | Controlled release flutamide composition |
AU671811B2 (en) * | 1991-12-18 | 1996-09-12 | Warner-Lambert Company | A process for the preparation of a solid dispersion |
US5340591A (en) * | 1992-01-24 | 1994-08-23 | Fujisawa Pharmaceutical Co., Ltd. | Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine |
-
1995
- 1995-06-20 SE SE9502244A patent/SE9502244D0/xx unknown
-
1996
- 1996-06-19 JP JP50378997A patent/JP4020331B2/ja not_active Expired - Lifetime
- 1996-06-19 CA CA002225286A patent/CA2225286C/en not_active Expired - Lifetime
- 1996-06-19 AT AT96921197T patent/ATE204466T1/de active
- 1996-06-19 AU AU62473/96A patent/AU695622B2/en not_active Expired
- 1996-06-19 DE DE0833611T patent/DE833611T1/de active Pending
- 1996-06-19 DK DK96921197T patent/DK0833611T3/da active
- 1996-06-19 PT PT96921197T patent/PT833611E/pt unknown
- 1996-06-19 EP EP96921197A patent/EP0833611B1/en not_active Expired - Lifetime
- 1996-06-19 US US08/973,902 patent/US6083518A/en not_active Expired - Lifetime
- 1996-06-19 DE DE69614689T patent/DE69614689T2/de not_active Expired - Lifetime
- 1996-06-19 WO PCT/SE1996/000806 patent/WO1997000670A1/en active IP Right Grant
- 1996-06-19 ES ES96921197T patent/ES2118677T3/es not_active Expired - Lifetime
- 1996-06-19 NZ NZ311208A patent/NZ311208A/xx not_active IP Right Cessation
- 1996-06-20 ZA ZA965237A patent/ZA965237B/xx unknown
-
1998
- 1998-07-29 HK HK98109537A patent/HK1008774A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
WO1997000670A1 (en) | 1997-01-09 |
AU695622B2 (en) | 1998-08-20 |
DE833611T1 (de) | 1999-01-07 |
JPH11508250A (ja) | 1999-07-21 |
AU6247396A (en) | 1997-01-22 |
DK0833611T3 (da) | 2001-10-08 |
DE69614689D1 (de) | 2001-09-27 |
JP4020331B2 (ja) | 2007-12-12 |
CA2225286C (en) | 2003-06-10 |
EP0833611A1 (en) | 1998-04-08 |
ZA965237B (en) | 1997-01-09 |
HK1008774A1 (en) | 1999-05-21 |
NZ311208A (en) | 1999-03-29 |
ATE204466T1 (de) | 2001-09-15 |
EP0833611B1 (en) | 2001-08-22 |
CA2225286A1 (en) | 1997-01-09 |
ES2118677T3 (es) | 2001-10-16 |
US6083518A (en) | 2000-07-04 |
PT833611E (pt) | 2002-01-30 |
DE69614689T2 (de) | 2002-06-27 |
ES2118677T1 (es) | 1998-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SE9502244D0 (sv) | A composition and a process for the preparation thereof | |
NO964939L (no) | Fremgangsmåte for fremstilling av virkestoffpreparater i form av en fast lösning av virkestoffet i en polymermatriks, samt virkestoffpreparater fremstilt ved hjelp av denne fremgangsmåte | |
FI103091B1 (fi) | Menetelmä viivästyneesti vapauttavan koostumuksen valmistamiseksi | |
MY121192A (en) | New compounds. | |
ES2170813T3 (es) | Acidos 2,2-dicloroalcanocarboxilicos, proceso para su preparacion, medicamentos que los contienen y su uso para tratar la resistencia a la insulina. | |
IS3966A (is) | Aðferð til framleiðslu á lyfjablöndum sem innihalda nifedipine | |
NO973646L (no) | Orale doseringsformer inneholdende et <beta>-laktam antibiotikum | |
ATE237316T1 (de) | Ibuprofen und domperidone enthaltende pharmazeutische zusammensetzungen | |
SE9403389D0 (sv) | Pharmaceutical composition containing derivattves of sex hormones | |
ATE175870T1 (de) | Pharmazeutische zubereitung zur rektalen verabreichung von pharmakologisch wirksamen verbindungen | |
ATE19472T1 (de) | Verwendung von 5-phenyl-1,4-benzodoazepinen zur herstellung von analgetisch wirksamen pharmazeutischen zubereitungen. | |
EP0305194A3 (en) | Veterinary composition | |
JPS57136503A (en) | Expellent for noxious mollusk | |
IL117734A (en) | Anellated beta-carbolines their preparation and pharmaceutical compositions containing them |